Venetoclax resistance and acquired BCL2 mutations in chronic lymphocytic leukemia

被引：163
|
作者：
Tausch, Eugen [1 ]
Close, William [1 ]
Dolnik, Anna [2 ]
Bloehdorn, Johannes [1 ]
Chyla, Brenda [3 ]
Bullinger, Lars [2 ]
Doehner, Hartmut [1 ]
Mertens, Daniel [1 ,4 ]
Stilgenbauer, Stephan [1 ,5 ]
机构：
[1] Ulm Univ, Dept Internal Med 3, Ulm, Germany
[2] Charite, Dept Hematol Oncol & Tumor Immunol, Berlin, Germany
[3] AbbVie, N Chicago, IL USA
[4] Deutsch Krebsforschungszentrum DKFZ, Cooperat Unit Mech Leukemogenesis, Heidelberg, Germany
[5] Saarland Univ, Sch Med, Dept Hematol Oncol & Rheumatol, Homburg, Germany
来源：
HAEMATOLOGICA | 2019年 / 104卷 / 09期
关键词：
ABT-199;
D O I：
10.3324/haematol.2019.222588
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页数：4
相关论文
共 50 条
  • [31] Concurrent rearrangements of BCL2, BCL3, and BCL11A genes in atypical chronic lymphocytic leukemia
    Podgornik, Helena
    Pretnar, Jozef
    Skopec, Barbara
    Andoljsek, Dusan
    Cernelc, Peter
    HEMATOLOGY, 2014, 19 (01) : 45 - 48
  • [32] Acquisition of the recurrent Gly101Val mutation in BCL2 confers resistance to venetoclax in patients with progressive chronic lymphocytic leukemia (Comment to Tausch et al.)
    Weiss, Jonathan
    Peifer, Martin
    Herling, Carmen D.
    Frenzel, Lukas P.
    Hallek, Michael
    HAEMATOLOGICA, 2019, 104 (11) : E540 - E540
  • [33] BCL2 AND BCL3 TRANSLOCATIONS IN CHRONIC LYMPHOCYTIC LEUKEMIA: PREVALENCE, ASSOCIATION WITH FISH AND PROGNOSTIC IMPACT
    Visentin, A.
    Bonaldi, L.
    Frezzato, F.
    Martines, A.
    Imbergamo, S.
    Martini, V.
    Trimarco, V.
    Severin, F.
    Raggi, F.
    Piazza, F.
    Conca, S.
    Cordiano, V.
    Scroccaro, R.
    Zambello, R.
    Facco, M.
    Semenzato, G.
    Trentin, L.
    HAEMATOLOGICA, 2016, 101 : S23 - S23
  • [34] Venetoclax for the treatment of chronic lymphocytic leukemia
    Gentile, Massimo
    Petrungaro, Annamaria
    Uccello, Giuseppina
    Vigna, Ernesto
    Recchia, Anna Grazia
    Caruso, Nadia
    Bossio, Sabrina
    De Stefano, Laura
    Palummo, Angela
    Storino, Francesca
    Martino, Massimo
    Morabito, Fortunato
    EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2017, 26 (11) : 1307 - 1316
  • [35] Venetoclax in the treatment of chronic lymphocytic leukemia
    Korycka-Wolowiec, Anna
    Wolowiec, Dariusz
    Kubiak-Mlonka, Aleksandra
    Robak, Tadeusz
    EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY, 2019, 15 (05) : 353 - 366
  • [36] Venetoclax and obinutuzumab in chronic lymphocytic leukemia
    Fischer, Kirsten
    Al-Sawaf, Othman
    Fink, Anna-Maria
    Dixon, Mark
    Bahlo, Jasmin
    Warburton, Simon
    Kipps, Thomas J.
    Weinkove, Robert
    Robinson, Sue
    Seiler, Till
    Opat, Stephen
    Owen, Carolyn
    Lopez, Javier
    Humphrey, Kathryn
    Humerickhouse, Rod
    Tausch, Eugen
    Frenzel, Lukas
    Eichhorst, Barbara
    Wendtner, Clemens-M.
    Stilgenbauer, Stephan
    Langerak, Anton W.
    van Dongen, Jacque J. M.
    Boettcher, Sebastian
    Ritgen, Matthias
    Goede, Valentin
    Mobasher, Mehrdad
    Hallek, Michael
    BLOOD, 2017, 129 (19) : 2702 - 2705
  • [37] Prognostic assessment of BCL2 C938A polymorphism in chronic lymphocytic leukemia (CLL)
    Rossi, Davide
    Rasi, Silvia
    Cerri, Michaela
    Deambrogi, Clara
    Cresta, Stefania
    Capello, Daniela
    Gaidano, Gianluca
    BLOOD, 2007, 110 (11) : 617A - 617A
  • [38] Venetoclax for the Treatment of Chronic Lymphocytic Leukemia
    Herbert Eradat
    Current Hematologic Malignancy Reports, 2019, 14 : 469 - 476
  • [39] Venetoclax (Venclexta) for Chronic Lymphocytic Leukemia
    不详
    MEDICAL LETTER ON DRUGS AND THERAPEUTICS, 2016, 58 (1500): : 101 - 102
  • [40] Venetoclax for the Treatment of Chronic Lymphocytic Leukemia
    Eradat, Herbert
    CURRENT HEMATOLOGIC MALIGNANCY REPORTS, 2019, 14 (05) : 469 - 476
12345